HAEMONETICS CORP (HAE) Q4 2025 10-Q Quarterly Report
Filed: Feb 5, 2026Period ending Dec 27, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR HAEMONETICS CORP (HAE) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 5, 2026 for the fiscal period ending Dec 27, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
HAEMONETICS CORP Q4 2025 10-Q Analysis
Risk Factors
- • Newly added geopolitical risk: heightened tensions in China, Taiwan, Russia, Ukraine, and the Middle East affecting operations
- • Most materially updated operational risk: supply chain disruptions due to climate change, labor strikes, terrorism, and cyber incidents
HAEMONETICS CORP Q4 2025 Quarterly FinancialsXBRL
Revenue
$339M
▼ -2.7% YoY▲ +3.6% QoQ
Net Income
$45M
▲ +19.3% YoY▲ +15.7% QoQ
Gross Margin
59.7%
▲ +418bp YoY▲ +21bp QoQ
Operating Margin
19.9%
▲ +295bp YoY▲ +201bp QoQ
Net Margin
13.2%
▲ +244bp YoY▲ +138bp QoQ
ROE
4.9%
▲ +77bp YoY
Total Assets
$2.5B
▼ -1.6% YoY
EPS (Diluted)
$0.95
▲ +28.4% YoY▲ +17.3% QoQ
Operating Cash Flow
$94M
▲ +113.8% YoY▼ -16.0% QoQ
Source: XBRL data from HAEMONETICS CORP Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on HAEMONETICS CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.